These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32796391)

  • 1. Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia.
    Buchanan RW; Weiner E; Kelly DL; Gold JM; Chen S; Zaranski J; Blatt F; Wehring H; Carpenter WT
    J Clin Psychopharmacol; 2020; 40(5):444-450. PubMed ID: 32796391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
    Buchanan RW; Kelly DL; Weiner E; Gold JM; Strauss GP; Koola MM; McMahon RP; Carpenter WT
    J Clin Psychopharmacol; 2017 Aug; 37(4):394-400. PubMed ID: 28590362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
    Kelly DL; Sullivan KM; McEvoy JP; McMahon RP; Wehring HJ; Gold JM; Liu F; Warfel D; Vyas G; Richardson CM; Fischer BA; Keller WR; Koola MM; Feldman SM; Russ JC; Keefe RS; Osing J; Hubzin L; August S; Walker TM; Buchanan RW
    J Clin Psychopharmacol; 2015 Aug; 35(4):374-81. PubMed ID: 26082974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.
    Ritsner MS; Bawakny H; Kreinin A
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):432-40. PubMed ID: 24548129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial.
    Chaudhry IB; Husain N; Husain MO; Hallak J; Drake R; Kazmi A; Rahman Ru; Hamirani MM; Kiran T; Mehmood N; Stirling J; Dunn G; Deakin B
    Trials; 2013 Apr; 14():101. PubMed ID: 23782463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
    Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.
    Smith RC; Amiaz R; Si TM; Maayan L; Jin H; Boules S; Sershen H; Li C; Ren J; Liu Y; Youseff M; Lajtha A; Guidotti A; Weiser M; Davis JM
    PLoS One; 2016; 11(1):e0143490. PubMed ID: 26730716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.
    Nasib LG; Sommer IE; Winter-van Rossum I; de Vries J; Gangadin SS; Oomen PP; Judge G; Blom RE; Luykx JJ; van Beveren NJM; Veen ND; Kroken RA; Johnsen EL
    Trials; 2020 Jun; 21(1):492. PubMed ID: 32513294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH; Jansen WT; Schipper J; Szegedi A
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
    Marx CE; Lee J; Subramaniam M; Rapisarda A; Bautista DC; Chan E; Kilts JD; Buchanan RW; Wai EP; Verma S; Sim K; Hariram J; Jacob R; Keefe RS; Chong SA
    Psychopharmacology (Berl); 2014 Sep; 231(17):3647-62. PubMed ID: 25030803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
    Zhou Y; Li G; Li D; Cui H; Ning Y
    J Psychopharmacol; 2018 May; 32(5):524-532. PubMed ID: 29493377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.